Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 1
2019 3
2020 2
2021 3
2022 4
2023 3
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Applications of single-cell and bulk RNA sequencing in onco-immunology.
Kuksin M, Morel D, Aglave M, Danlos FX, Marabelle A, Zinovyev A, Gautheret D, Verlingue L. Kuksin M, et al. Among authors: morel d. Eur J Cancer. 2021 May;149:193-210. doi: 10.1016/j.ejca.2021.03.005. Epub 2021 Apr 15. Eur J Cancer. 2021. PMID: 33866228 Free article. Review.
Radio-induced lymphopenia in the era of anti-cancer immunotherapy.
de Kermenguy F, Meziani L, Mondini M, Clémenson C, Morel D, Deutsch E, Robert C. de Kermenguy F, et al. Among authors: morel d. Int Rev Cell Mol Biol. 2023;378:1-30. doi: 10.1016/bs.ircmb.2023.03.002. Epub 2023 Apr 3. Int Rev Cell Mol Biol. 2023. PMID: 37438014 Review.
KRASG12C inhibition using MRTX1257: a novel radio-sensitizing partner.
Laurent PA, Milic M, Quevrin C, Meziani L, Liu W, Morel D, Signolle N, Clémenson C, Levy A, Mondini M, Deutsch E. Laurent PA, et al. Among authors: morel d. J Transl Med. 2023 Oct 31;21(1):773. doi: 10.1186/s12967-023-04619-0. J Transl Med. 2023. PMID: 37907934 Free PMC article.
Otorhinolaryngological Toxicities of New Drugs in Oncology.
Hartl DM, Morel D, Saavedra E, Massard C, Rinaldo A, Saba NF, Ferlito A, Soria JC. Hartl DM, et al. Among authors: morel d. Adv Ther. 2017 Apr;34(4):866-894. doi: 10.1007/s12325-017-0512-0. Epub 2017 Mar 17. Adv Ther. 2017. PMID: 28315206 Review.
PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer.
Chabanon RM, Morel D, Eychenne T, Colmet-Daage L, Bajrami I, Dorvault N, Garrido M, Meisenberg C, Lamb A, Ngo C, Hopkins SR, Roumeliotis TI, Jouny S, Hénon C, Kawai-Kawachi A, Astier C, Konde A, Del Nery E, Massard C, Pettitt SJ, Margueron R, Choudhary JS, Almouzni G, Soria JC, Deutsch E, Downs JA, Lord CJ, Postel-Vinay S. Chabanon RM, et al. Among authors: morel d. Cancer Res. 2021 Jun 1;81(11):2888-2902. doi: 10.1158/0008-5472.CAN-21-0628. Cancer Res. 2021. PMID: 33888468
An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer.
Levy A, Morel D, Texier M, Sun R, Durand-Labrunie J, Rodriguez-Ruiz ME, Racadot S, Supiot S, Magné N, Cyrille S, Louvel G, Massard C, Verlingue L, Bouquet F, Bustillos A, Bouarroudj L, Quevrin C, Clémenson C, Mondini M, Meziani L, Tselikas L, Bahleda R, Hollebecque A, Deutsch E. Levy A, et al. Among authors: morel d. Mol Cancer. 2024 Mar 23;23(1):61. doi: 10.1186/s12943-024-01970-8. Mol Cancer. 2024. PMID: 38519913 Free PMC article. Clinical Trial.
19 results